Kieran F Docherty, John J V McMurray, Rafael Diaz, G Michael Felker, Marco Metra, Scott D Solomon, Kirkwood F Adams, Michael Böhm, Douglas Marshall Brinkley, Luis E Echeverria, Assen R Goudev, Jonathan G Howlett, Mayanna Lund, Piotr Ponikowski, Mehmet B Yilmaz, Faiez Zannad, Brian L Claggett, Zi Michael Miao, Siddique A Abbasi, Punag Divanji, Stephen B Heitner, Stuart Kupfer, Fady I Malik, John R Teerlink
BACKGROUND: In the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial, omecamtiv mecarbil, compared with placebo, reduced the risk of worsening heart failure (HF) events or cardiovascular death in patients with HF and reduced ejection fraction (HFrEF). The primary aim of this prespecified analysis was to evaluate the safety and efficacy of omecamtiv mecarbil by randomization setting i.e., whether participants were enrolled as outpatients or inpatients...
September 6, 2023: Journal of Cardiac Failure